Survival Benefit With Nivolumab Still Seen at 5 Years in Melanoma, RCC, and NSCLC

Source: Targeted Oncology, September 2019

Nivolumab (Opdivo) demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma (RCC), and non–small cell lung cancer (NSCLC), according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.

Patients with melanoma treated with nivolumab had an objective response rate (ORR) of 31.8% (95% CI, 23.1%-41.5%), 29.4% (95% CI, 15.1%-47.5%) with RCC, and 17.1% (95% CI, 11.0%-24.7%) with NSCLC.

“The results of this study suggest that survival benefits reported in the more limited follow-up of recent nivolumab randomized clinical trials may persist for prolonged periods in some patients, extending to at least 5 years,” the study authors, led by Suzanne L. Topalian, MD, wrote in their report published recently in JAMA Oncology. “The estimated 5-year survival rates…exceed survival rates expected from conventional second-line or third-line therapies available for patients at the time that this trial was conducted.”

Read the original full article